Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder.
作者信息
Andrade Chittaranjan
机构信息
Dept. of Clinical Psychopharmacology and Neurotoxicology, National Institute of Mental Health and Neurosciences, Bangalore, Karnataka, India.
出版信息
Indian J Psychol Med. 2023 Nov;45(6):651-653. doi: 10.1177/02537176231160264. Epub 2023 Mar 29.
Abstract
摘要
相似文献
1
Therapeutic Compatibility of Orally Administered Racemic Ketamine with Modafinil, a CYP3A4 Enzyme Inducer, in Treatment-Refractory Major Depressive Disorder.
Indian J Psychol Med. 2023 Nov;45(6):651-653. doi: 10.1177/02537176231160264. Epub 2023 Mar 29.
2
Leveraging Human Plasma-Derived Small Extracellular Vesicles as Liquid Biopsy to Study the Induction of Cytochrome P450 3A4 by Modafinil.
Clin Pharmacol Ther. 2022 Feb;111(2):425-434. doi: 10.1002/cpt.2440. Epub 2021 Nov 2.
3
The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Recommendations for the Use of Racemic Ketamine in Adults with Major Depressive Disorder: Recommandations Du Groupe De Travail Du Réseau Canadien Pour Les Traitements De L'humeur Et De L'anxiété (Canmat) Concernant L'utilisation De La Kétamine Racémique Chez Les Adultes Souffrant De Trouble Dépressif Majeur.
Can J Psychiatry. 2021 Feb;66(2):113-125. doi: 10.1177/0706743720970860. Epub 2020 Nov 11.
4
Compounded intranasal racemic ketamine for major depressive disorder: A case report.
Exp Clin Psychopharmacol. 2021 Dec;29(6):750-754. doi: 10.1037/pha0000437. Epub 2021 Mar 4.
5
A randomized, crossover comparison of ketamine and electroconvulsive therapy for treatment of major depressive episodes: a Canadian biomarker integration network in depression (CAN-BIND) study protocol.
BMC Psychiatry. 2020 Jun 2;20(1):268. doi: 10.1186/s12888-020-02672-3.
6
Clinical predictors of depressive symptom remission and response after racemic ketamine and esketamine infusion in treatment-resistant depression.
Hum Psychopharmacol. 2022 Jul;37(4):e2836. doi: 10.1002/hup.2836. Epub 2022 Feb 18.
7
Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Clin Pharmacokinet. 2008;47(1):61-74. doi: 10.2165/00003088-200847010-00006.
8
Effects of medetomidine and its active enantiomer dexmedetomidine on N-demethylation of ketamine in canines determined in vitro using enantioselective capillary electrophoresis.
Electrophoresis. 2015 Nov;36(21-22):2703-2712. doi: 10.1002/elps.201500147. Epub 2015 Aug 20.
9
Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT).
Int J Neuropsychopharmacol. 2022 May 27;25(5):339-349. doi: 10.1093/ijnp/pyab088.
10
Comparative efficacy, tolerability and acceptability of intravenous racemic ketamine with intranasal esketamine, aripiprazole and lithium as augmentative treatments for treatment-resistant unipolar depression: A systematic review and network meta-analysis.
J Affect Disord. 2024 Feb 1;346:49-56. doi: 10.1016/j.jad.2023.11.023. Epub 2023 Nov 8.
引用本文的文献
1
A systematic scoping review of Indian literature on ketamine use for treating psychiatric disorders.
Ind Psychiatry J. 2025 May-Aug;34(2):167-178. doi: 10.4103/ipj.ipj_376_24. Epub 2025 May 22.
本文引用的文献
1
Pharmacogenetic and drug interaction aspects on ketamine safety in its use as antidepressant - implications for precision dosing in a global perspective.
Br J Clin Pharmacol. 2022 Dec;88(12):5149-5165. doi: 10.1111/bcp.15467. Epub 2022 Aug 5.
2
Oral racemic ketamine for common clinical contexts in patients with major depressive disorder: An important intervention that treatment guidelines may never include.
Bipolar Disord. 2022 Mar;24(2):113-114. doi: 10.1111/bdi.13155. Epub 2021 Nov 23.
3
Oral Ketamine for Depression, 2: Practical Considerations.
J Clin Psychiatry. 2019 Apr 9;80(2):19f12838. doi: 10.4088/JCP.19f12838.
4
Metabolism and metabolomics of ketamine: a toxicological approach.
Forensic Sci Res. 2017 Feb 20;2(1):2-10. doi: 10.1080/20961790.2017.1285219. eCollection 2017.
5
An update on the role of intestinal cytochrome P450 enzymes in drug disposition.
Acta Pharm Sin B. 2016 Sep;6(5):374-383. doi: 10.1016/j.apsb.2016.07.012. Epub 2016 Aug 4.
6
Cytochrome P450-mediated metabolism in the human gut wall.
J Pharm Pharmacol. 2009 May;61(5):541-58. doi: 10.1211/jpp/61.05.0002.
7
Intestinal first-pass metabolism of CYP3A4 substrates.
Drug Metab Pharmacokinet. 2008;23(2):87-94. doi: 10.2133/dmpk.23.87.
8
Clinical pharmacokinetic profile of modafinil.
Clin Pharmacokinet. 2003;42(2):123-37. doi: 10.2165/00003088-200342020-00002.
Zotero 插件